Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease.

Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, Magis-Escurra C, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Apr 18. pii: 1900118. doi: 10.1183/13993003.00118-2019. [Epub ahead of print] No abstract available.

PMID:
31000671
2.

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.

Clin Pharmacokinet. 2019 Apr 17. doi: 10.1007/s40262-019-00763-3. [Epub ahead of print]

PMID:
30997650
3.

Pharmacokinetics, safety and tolerability of the novel β-hCG derived immunomodulatory compound, EA-230.

van Groenendael R, Aarnoutse R, Kox M, van Eijk L, Pickkers P.

Br J Clin Pharmacol. 2019 Mar 29. doi: 10.1111/bcp.13942. [Epub ahead of print]

PMID:
30924163
4.

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C.

PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.

5.

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin.

van Beek SW, Ter Heine R, Keizer RJ, Magis-Escurra C, Aarnoutse RE, Svensson EM.

Clin Pharmacokinet. 2019 Jun;58(6):815-826. doi: 10.1007/s40262-018-00732-2.

PMID:
30671890
6.

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.

Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J.

J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.

PMID:
30649327
7.

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

Te Brake LHM, Boeree MJ, Aarnoutse RE.

Am J Respir Crit Care Med. 2019 May 1;199(9):1166-1167. doi: 10.1164/rccm.201811-2101LE. No abstract available.

8.

Protein binding of rifampicin is not saturated when using high-dose rifampicin.

Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM; PanACEA-MAMS-TB-01 Team .

J Antimicrob Chemother. 2019 Apr 1;74(4):986-990. doi: 10.1093/jac/dky527.

PMID:
30597025
9.

Intensified antibiotic treatment of tuberculosis meningitis.

Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):267-288. doi: 10.1080/17512433.2019.1552831. Epub 2019 Feb 12. Review.

PMID:
30474434
10.

Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.

Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, Achmad TH, Colbers A, Te Brake L, van Crevel R, Ruslami R, Aarnoutse R.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01014-18. doi: 10.1128/AAC.01014-18. Print 2018 Dec.

11.

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients.

Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, Burger DM, Santoso P, van Crevel R, Alisjahbana B, Aarnoutse RE, Ruslami R; on behalf of the TANDEM Consortium.

Clin Pharmacol Ther. 2019 Mar;105(3):730-737. doi: 10.1002/cpt.1232. Epub 2018 Oct 29.

PMID:
30222857
12.

High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study).

Cresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R, Meya D, Boulware DR, Elliott AM.

Wellcome Open Res. 2018 Jul 10;3:83. doi: 10.12688/wellcomeopenres.14691.1. eCollection 2018.

13.

A treatment-support intervention evaluated in South African paediatric populations with HIV infection or tuberculous meningitis.

van Elsland SL, Peters RPH, Kok MO, van Toorn R, Springer P, Cotton MF, Grobbelaar CJ, Aarnoutse R, van Furth AM.

Trop Med Int Health. 2018 Oct;23(10):1129-1140. doi: 10.1111/tmi.13134. Epub 2018 Sep 3.

PMID:
30075490
14.

The stability of antimycobacterial drugs in media used for drug susceptibility testing.

Schoutrop ELM, Brouwer MAE, Jenniskens JCA, Ferro BE, Mouton JW, Aarnoutse RE, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):305-308. doi: 10.1016/j.diagmicrobio.2018.06.015. Epub 2018 Jun 27.

PMID:
30025972
15.

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax HI, Aarnoutse RE, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01354-18. doi: 10.1128/AAC.01354-18. Print 2018 Sep.

16.

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R.

Clin Infect Dis. 2018 Jun 18;67(1):34-41. doi: 10.1093/cid/ciy026.

17.

Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.

Martial LC, Kerkhoff J, Martinez N, Rodríguez M, Coronel R, Molinas G, Roman M, Gomez R, Aguirre S, Jongedijk E, Huisman J, Touw DJ, Pérez D, Chaparro G, Gonzalez F, Aarnoutse RE, Alffenaar JW, Magis-Escurra C.

Int J Antimicrob Agents. 2018 Jul;52(1):109-113. doi: 10.1016/j.ijantimicag.2018.04.020. Epub 2018 May 8.

PMID:
29751121
18.

Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole.

Martial LC, van den Hombergh E, Tump C, Halmingh O, Burger DM, van Maarseveen EM, Brüggemann RJ, Aarnoutse RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 1;1089:16-23. doi: 10.1016/j.jchromb.2018.04.039. Epub 2018 Apr 27.

PMID:
29747155
19.

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations.

Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Moodley M, Boeree MJ, Simonsson USH.

J Infect Dis. 2018 Aug 14;218(6):991-999. doi: 10.1093/infdis/jiy242.

PMID:
29718390
20.

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313. doi: 10.1093/jac/dky152.

21.

Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.

Chabala C, Turkova A, Thomason MJ, Wobudeya E, Hissar S, Mave V, van der Zalm M, Palmer M, Kapasa M, Bhavani PK, Balaji S, Raichur PA, Demers AM, Hoddinott G, Owen-Powell E, Kinikar A, Musoke P, Mulenga V, Aarnoutse R, McIlleron H, Hesseling A, Crook AM, Cotton M, Gibb DM; SHINE trial team.

Trials. 2018 Apr 19;19(1):237. doi: 10.1186/s13063-018-2608-5.

22.

Determination of protein-unbound, active rifampicin in serum by ultrafiltration and Ultra Performance Liquid Chromatography with UV detection. A method suitable for standard and high doses of rifampicin.

van Ewijk-Beneken Kolmer EWJ, Teulen MJA, van den Hombergh ECA, van Erp NE, Te Brake LHM, Aarnoutse RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 15;1063:42-49. doi: 10.1016/j.jchromb.2017.08.004. Epub 2017 Aug 4.

23.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

24.

The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box.

Te Brake LHM, de Knegt GJ, de Steenwinkel JE, van Dam TJP, Burger DM, Russel FGM, van Crevel R, Koenderink JB, Aarnoutse RE.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:271-291. doi: 10.1146/annurev-pharmtox-010617-052438. Epub 2017 Jul 17.

PMID:
28715978
25.

Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation.

Martial LC, Hoogtanders KEJ, Schreuder MF, Cornelissen EA, van der Heijden J, Joore MA, Van Maarseveen EM, Burger DM, Croes S, Brüggemann RJM, Aarnoutse RE.

Ther Drug Monit. 2017 Aug;39(4):412-421. doi: 10.1097/FTD.0000000000000422.

PMID:
28700522
26.

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.

Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH.

Clin Pharmacol Ther. 2018 Apr;103(4):674-683. doi: 10.1002/cpt.778. Epub 2017 Aug 7.

27.

Hybrid 18F-FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy.

Goorts B, Vöö S, van Nijnatten TJA, Kooreman LFS, de Boer M, Keymeulen KBMI, Aarnoutse R, Wildberger JE, Mottaghy FM, Lobbes MBI, Smidt ML.

Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1796-1805. doi: 10.1007/s00259-017-3745-x. Epub 2017 Jun 10.

PMID:
28600647
28.

Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.

Smolders EJ, Colbers A, de Kanter CTMM, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, Drenth JPH, Aarnoutse RE, Tack CJ, Burger DM.

Br J Clin Pharmacol. 2017 Oct;83(10):2225-2234. doi: 10.1111/bcp.13323. Epub 2017 Jun 6.

29.

Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0.

Aarnoutse R, de Vos-Geelen JMPGM, Penders J, Boerma EG, Warmerdam FARM, Goorts B, Olde Damink SWM, Soons Z, Rensen SSM, Smidt ML.

Int J Colorectal Dis. 2017 Jul;32(7):1077-1084. doi: 10.1007/s00384-017-2819-3. Epub 2017 Apr 25.

30.

Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.

Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, Meintjes G, Misra UK, Mai NTH, Ruslami R, Seddon JA, Solomons R, van Toorn R, Figaji A, McIlleron H, Aarnoutse R, Schoeman JF, Wilkinson RJ, Thwaites GE; Tuberculous Meningitis International Research Consortium.

Clin Infect Dis. 2017 Feb 15;64(4):501-509. doi: 10.1093/cid/ciw757. Review.

31.

Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.

de Knegt GJ, van der Meijden A, de Vogel CP, Aarnoutse RE, de Steenwinkel JE.

Int J Antimicrob Agents. 2017 Mar;49(3):302-307. doi: 10.1016/j.ijantimicag.2016.11.027. Epub 2017 Feb 2.

PMID:
28162983
32.

Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring.

Martial LC, Aarnoutse RE, Mulder M, Schellekens A, Brüggemann RJM, Burger DM, Schene AH, Batalla A.

Eur Neuropsychopharmacol. 2017 Mar;27(3):205-216. doi: 10.1016/j.euroneuro.2017.01.009. Epub 2017 Jan 24. Review.

PMID:
28130001
33.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

34.

Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children.

Martial LC, Aarnoutse RE, Schreuder MF, Henriet SS, Brüggemann RJ, Joore MA.

PLoS One. 2016 Dec 12;11(12):e0167433. doi: 10.1371/journal.pone.0167433. eCollection 2016.

35.

A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients.

Martial LC, Verstegen RH, Cornelissen EA, Aarnoutse RE, Schreuder MF, Brüggemann RJ.

J Pharm Pharmacol. 2016 Nov;68(11):1366-1372. doi: 10.1111/jphp.12639. Epub 2016 Sep 27.

PMID:
27669677
36.

Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.

Te Brake LH, van den Heuvel JJ, Buaben AO, van Crevel R, Bilos A, Russel FG, Aarnoutse RE, Koenderink JB.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7105-7114. Print 2016 Dec.

37.

Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients.

Yunivita V, Dian S, Ganiem AR, Hayati E, Hanggono Achmad T, Purnama Dewi A, Teulen M, Meijerhof-Jager P, van Crevel R, Aarnoutse R, Ruslami R.

Int J Antimicrob Agents. 2016 Oct;48(4):415-21. doi: 10.1016/j.ijantimicag.2016.06.016. Epub 2016 Jul 26.

PMID:
27526979
38.

Measuring Plasma Concentrations of Ribavirin: First Report From a Quality Control Program.

Smolders EJ, Kan R, de Kanter CT, van Luin M, Aarnoutse RE, Touw DJ, Burger DM.

Ther Drug Monit. 2016 Oct;38(5):646-7. doi: 10.1097/FTD.0000000000000319. No abstract available.

PMID:
27355493
39.

Therapy for Tuberculous Meningitis.

van Crevel R, Ruslami R, Aarnoutse R.

N Engl J Med. 2016 Jun 2;374(22):2187. doi: 10.1056/NEJMc1602291. No abstract available.

PMID:
27248635
40.

Does Weight Impact Anidulafungin Pharmacokinetics?

Lempers VJ, van Rongen A, van Dongen EP, van Ramshorst B, Burger DM, Aarnoutse RE, Knibbe CA, Brüggemann RJ.

Clin Pharmacokinet. 2016 Oct;55(10):1289-1294. doi: 10.1007/s40262-016-0401-8.

41.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M.

BMC Med. 2016 Mar 23;14:51. doi: 10.1186/s12916-016-0597-3.

42.

Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.

Lempers VJ, van den Heuvel JJ, Russel FG, Aarnoutse RE, Burger DM, Brüggemann RJ, Koenderink JB.

Antimicrob Agents Chemother. 2016 May 23;60(6):3372-9. doi: 10.1128/AAC.02931-15. Print 2016 Jun.

43.

Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients.

Martial LC, Jacobs BA, Cornelissen EA, de Haan AF, Koch BC, Burger DM, Aarnoutse RE, Schreuder MF, Brüggemann RJ.

Pediatr Transplant. 2016 Jun;20(4):492-9. doi: 10.1111/petr.12695. Epub 2016 Feb 29.

PMID:
26923724
44.

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.

Te Brake LH, Russel FG, van den Heuvel JJ, de Knegt GJ, de Steenwinkel JE, Burger DM, Aarnoutse RE, Koenderink JB.

Tuberculosis (Edinb). 2016 Jan;96:150-7. doi: 10.1016/j.tube.2015.08.004. Epub 2015 Oct 9.

PMID:
26682943
45.

Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

Martial LC, Brüggemann RJ, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Muilwijk EW, Verweij PE, Burger DM, Aarnoutse RE, Pickkers P, Dorlo TP.

Clin Pharmacokinet. 2016 Jun;55(6):723-33. doi: 10.1007/s40262-015-0347-2.

46.

Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting.

de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, Semvua HH, Kiwango KW, Aarnoutse RE, Nieuwkerk PT, Kibiki GS.

AIDS Behav. 2016 May;20(5):1097-107. doi: 10.1007/s10461-015-1254-0.

PMID:
26604004
47.

A Step toward an Optimized Rifampin Dose Completed.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):525-6. doi: 10.1164/rccm.201506-1061LE. No abstract available.

PMID:
26278799
48.

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE.

Clin Pharmacol Ther. 2015 Dec;98(6):622-9. doi: 10.1002/cpt.202. Epub 2015 Oct 22.

49.

Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice.

Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, Brüggemann RJ.

Curr Opin Pharmacol. 2015 Oct;24:38-44. doi: 10.1016/j.coph.2015.07.002. Epub 2015 Jul 25. Review.

PMID:
26218924
50.

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.

Supplemental Content

Loading ...
Support Center